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of Southampton, Southampton, UKA B S T R A C TObjectives: To determine the cost-effectiveness of complete revascu-
larization at index admission compared with infarct-related artery
(IRA) treatment only, in patients with multivessel disease undergoing
primary percutaneous coronary intervention (P-PCI) for ST-segment
elevation myocardial infarction. Methods: An economic evaluation of
a multicenter randomized trial was conducted, comparing complete
revascularization at index admission to IRA-only P-PCI in patients
with multivessel disease (12-month follow-up). Overall hospital costs
(costs for P-PCI procedure(s), hospital length of stay, and any sub-
sequent re-admissions) were estimated. Outcomes were major
adverse cardiac events (MACEs, a composite of all-cause death,
recurrent myocardial infarction, heart failure, and ischemia-driven
revascularization) and quality-adjusted life-years (QALYs) derived
from the three-level EuroQol ﬁve-dimensional questionnaire. Multiple
imputation was undertaken. The mean incremental cost and effect,
with associated 95% conﬁdence intervals, the incremental cost-
effectiveness ratio, and the cost-effectiveness acceptability curve
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estimated to be –£215.96 (–£1390.20 to £958.29), compared with IRA-
only, with a per-patient mean reduction in MACEs of 0.170 (0.044 to
0.296) and a QALY gain of 0.011 (0.019 to 0.041). According to the
cost-effectiveness acceptability curve, the probability of complete
revascularization being cost-effective was estimated to be 72.0% at a
willingness-to-pay threshold value of £20,000 per QALY. Conclusions:
Complete revascularization at index admission was estimated to be
more effective (in terms of MACEs and QALYs) and cost-effective
(overall costs were estimated to be lower and complete revasculariza-
tion thereby dominated IRA-only). There was, however, some uncer-
tainty associated with this decision.
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Cardiovascular disease is a leading cause of mortality in the
United Kingdom, with more than 150,000 deaths each year andannual costs of more than £15 billion [1]. Primary percutaneous
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inserting a catheter via the groin or arm. A small balloon is then
inﬂated in the narrowed artery to move the obstructing fatty
tissue/clot and to widen the artery. Usually, at least one stent is
then permanently implanted to hold the artery open and improve
blood ﬂow to the heart [2]. Of patients presenting with STEMI,
40% to 65% are estimated to have bystander stenosis in non–
infarct-related arteries (N-IRAs) (multivessel disease) [3]. Until
recently, treatment of the IRA alone was the internationally
recommended strategy [4–6]. There is, however, growing trial
evidence [7–9] that the additional treatment of N-IRAs (complete
revascularization) is associated with fewer adverse cardiac
events, and the previous “do-not-do” guidance by the American
College of Cardiology has now been withdrawn [10]. Although
these results need to be conﬁrmed in larger trials, the emerging
clinical evidence presents the opportunity to examine the cost-
effectiveness of complete versus infarct-only revascularization.
Revascularization may be associated with increased initial pro-
cedure costs, but it is important to also assess whether these
costs are offset by reduced future hospital admissions and fewer
adverse events. Here, we report an economic evaluation [11,12],
which was conducted alongside the Complete versus Lesion-only
Primary PCI Trial (CvLPRIT) [8], to assess whether complete
revascularization constitutes a cost-effective use of health care
resources. We are not aware of any previous economic evalua-
tions of complete revascularization in this patient group.Methods
Participants
As previously described [8], the CvLPRIT was a multicenter
randomized trial comparing complete revascularization with
IRA-only P-PCI for patients with bystander multivessel coronary
artery disease. Patients were eligible if, after angiography, at least
one other artery had a signiﬁcant (70%) stenosis in addition to the
occluded IRA. Inclusion and exclusion criteria are listed in the
Appendix Table in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2017.02.002. Patients were randomized to either
the IRA-only strategy or to complete revascularization, under-
taken either at the time of P-PCI or during that index admission.
Randomization was via an automated 24-hour telephone ran-
domization system and stratiﬁed by infarct location (anterior/
nonanterior) and symptom onset (r3 hours or 43 hours). Patients
were followed up for 12 months postrandomization. The study was
approved by the National Research Ethics Service (NRES) Committee
East Midlands Derby (reference number: 11/H0405/4).
Costs
Costs were estimated from the perspective of the UK National
Health Service (NHS). Speciﬁcally, index admission P-PCI proce-
dure(s) costs (based on procedure time, consumables, and equip-
ment [e.g., catheter, balloon, and stents] used for both IRA and any
N-IRA interventions performed, for both the initial procedure and
any staged procedure), hospital length of stay costs (including time
in critical care/high dependency and/or intensive care), and the
costs of any hospital re-admissions were estimated. All centers
were asked to prospectively collect detailed information on the PCI
procedure and admission on study-speciﬁc case record forms.
Follow-up data (including hospital re-admissions) were subse-
quently collected via telephone (6-month postrandomization)
and face-to-face appointment (12-month postrandomization). Unit
costs (in Great Britain pound [£] for the 2012–2013 ﬁnancial year)
were assigned to all items of resource use. When national unit cost
data [13–15] were not available, for example, for stents and otherP-PCI devices, we conducted a survey of participating centers to
estimate the average cost for each item. Index admission (P-PCI
procedure(s) and hospital length of stay) and re-admission costs
were combined to estimate overall hospital costs.
In a subsample of sites (three out of the seven centers), all
patients were asked to complete an additional resource use
questionnaire at the 12-month visit. They were asked to report
(1) all postdischarge health professional visits in the previous 12
months, (2) whether they were in paid employment at the point
of randomization, and (3) whether they had returned to work at
the 12-month follow-up point. Only the ﬁrst three enrolled sites
were asked to complete the additional resource use question-
naire because of the associated burden for staff and patients.
Other sites that came on board later to boost recruitment were
not asked to complete the additional resource use questionnaire.
Health professional visits (including general practitioner visits,
outpatient attendances, and therapist contacts) were costed as
mentioned earlier and added to overall hospital costs to estimate
overall NHS and personal social services (PSS) costs.
Outcomes
The primary outcome measure was a major adverse cardiac event
(MACE) occurring within 12 months of randomization (a composite
of all-cause mortality, recurrent myocardial infarction, heart fail-
ure, and need for repeat revascularization [PCI or coronary artery
bypass grafting]), as deﬁned in Appendix 2 of the main trial article
[8]. Hospitals recorded MACE data, informed by telephone contact
with the patients at 6 months postrandomization and hospital
visits at approximately 12 months. Clinicians blinded to the
randomization group adjudicated all MACEs. All MACEs across
the 12-month follow-up period were included in the cost-
effectiveness analyses (the primary end point in the clinical article
was time to ﬁrst MACE [8]). In line with the National Institute for
Health and Care Excellence methods guide [12], quality of life was
measured using the three-level EuroQol ﬁve-dimensional ques-
tionnaire (EQ-5D) [16] at initial discharge (baseline) and at 12
months postintervention. Utility scores (a scale in which 0 is equal
to death and 1 is full health) [11] were derived from the UK York A1
tariff [17] and converted into quality-adjusted life-years (QALYs)
using the area under the curve approach, with linear interpolation
between the baseline EQ-5D and the 12-month follow-up point
[18]. For patients who died during follow-up, an EQ-5D score of 0
was assigned at their date of death [19].
Analyses
The problem of missing data is common in randomized trials and
can lead to bias and lack of precision [20]. As recommended for
within-trial analysis of cost-effectiveness [20], patterns of missing
data were examined to infer the assumed missing data mechanism,
and complete case analysis [21] did not constitute the base-case
analysis. Health professional visit costs were requested for only
three of the centers and these costs constituted only a small
component of the total cost (see Results section). Pragmatically, it
was therefore considered inappropriate to undertake either com-
plete case analysis or imputation for this variable and no further
analysis was thereby undertaken for health professional visit costs
or overall NHS and PSS costs. To impute missing data, multiple
imputation was undertaken [20], where the “mi impute” command
(Stata 12.1 [StataCorp LP, College Station, TX] [22]) was used to create
20 data sets (a rule of thumb is that the number of data sets should
equal the percentage of missing data [23]), which were then pooled
using Rubin rules [24]. In addition to the costs (procedure time,
consumables and equipment, hospital length of stay, and re-
admissions) and outcomes (baseline and 12-month EQ-5D scores),
the multiple imputation model included variables (P o 0.10)
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symptom onset at randomization [r3 hours or 43 hours], infarct
location [anterior/nonanterior], medical history of treated hyper-
cholesterolemia, medical history of treated diabetes, age, death,
center, sex, and treatment allocation). Baseline and 12-month EQ-5D
scores were included, rather than individual dimension scores,
because if EQ-5D data were missing, then it would generally be for
the whole questionnaire. Nevertheless, disaggregated costs were
used (and then combined to estimate overall hospital costs) because
different resource items had different levels of missing data.
Cost and outcome data were analyzed simultaneously using
bivariate regression, which is generally robust for skewed data
and allows for any correlation between costs and effects [25]. We
followed the intention-to-treat approach, in which patients were
analyzed according to the group to which they were allocated
(regardless of treatment received). All the regressions included
age and sex as covariates. The QALY regression also included the
baseline EQ-5D as a covariate [18]. This enabled the mean
incremental cost between the two groups (mean difference in
cost) and the mean incremental effect (the mean difference in
both the total number of MACEs/QALYs) to be estimated.
The incremental cost-effectiveness ratio (ICER), deﬁned as
mean incremental cost/mean incremental effect [12], for com-
plete revascularization, compared with IRA-only, was subse-
quently estimated. If one intervention was both less costly and
more effective, it was not necessary as that intervention would be
categorized as dominant [11]. The ICER can be used to assess
whether the extra cost of the intervention (in this case, complete
revascularization) constitutes value for money. In the United
Kingdom, the National Institute for Health and Care Excellence
refers to a cost-effectiveness threshold (λ) value of £20,000 to
£30,000 per QALY [12]. As such, if complete revascularization had
an ICER (incremental cost per QALY) lower than this level, then
we would consider it to be cost-effective.
To estimate the level of uncertainty associated with the
decision regarding cost-effectiveness, bootstrap resampling [26]
(with 250 replications drawn from each of the 20 imputed data
sets [20]) was used to depict results on the cost-effectiveness
plane and the cost-effectiveness acceptability curve (CEAC). The
cost-effectiveness plane depicts estimates of the mean incre-
mental cost and the mean incremental effect [27], whereas theTable 1 – Levels of resource use.
Resource use
IRA-only, N
N-IRA completed in same sitting, N
N-IRA completed in separate (staged) sitting, N
P-PCI procedure time (min), mean  SD
Staged N-IRA procedure time (min), mean  SD
P-PCI and any staged N-IRA procedure time (min), mean  SD
Glycoprotein IIb/IIIa inhibitors, N
Bivalirudin, N
Bare metal stents, N
Drug-eluting stents, N
Total number of stents (used per patient), mean  SD
Thrombus aspiration, N
Radial access, N
Initial hospital length of stay per patient (d), mean  SD
Re-admissions (all), length of stay per patient (d), mean  SD
IRA, infarct-related artery; n, number of patients for whom data were
primary percutaneous coronary intervention.
* One IRA patient had an index admission length of stay of 65 d and anot
the median value in both arms is 3 d.CEAC depicts the probability of the intervention being cost-
effective at various “willingness-to-pay” thresholds compared
with standard care [28]. In addition, the expected value of perfect
information (EVPI), which provides a guide to the upper limit of
the value of further research [29], was also calculated at a λ value
of £20,000 per QALY.
Finally, sensitivity analyses were performed to assess the
robustness of the aforementioned base-case analysis conclusions
to changes in key assumptions [11]. First, a per protocol analysis
(SA1) was conducted, excluding patients who did not receive the
intervention to which they were allocated (crossovers). Next, a
complete case analysis (SA2) [21] was conducted for comparison,
in which patients were included only if they had available data
for all costs and outcomes. All analyses were performed in Stata
version 12.1 [22] and because of the 12-month follow-up period,
no discounting [11] was undertaken.Results
Participants
Recruitment took place between May 2011 and May 2013 at seven
participating UK centers. In total, 296 patients were randomized.
Baseline demographic and clinical characteristics were similar in
both arms; 85.3% of complete revascularization patients were
male and the mean age was 64.6 years compared with 76.7%
males and a mean age of 65.3 years for IRA-only patients. In the
12-month follow-up period, 14 died and 19 were lost to follow-up.
A national database search indicated none of these lost to follow-
up patients died during the study period [8].
Costs
Table 1 presents the levels of resource use for both groups on the
basis of available data. Mean P-PCI procedure(s) time (including
any staged procedures) was higher in the complete revasculari-
zation arm (76.6 minutes compared with 45.2 minutes for the
IRA-only arm; P o 0.001), as were the number of stents (2.84 per
patient vs. 1.45 per patient; P o 0.001). Other resource item use
was broadly similar between arms (see Table 1).Complete (n ¼ 150) IRA-only (n ¼ 146)
11 (crossover) (n ¼ 150) 139 (n ¼ 146)
97 (n ¼ 150) 7 (crossover) (n ¼ 146)
42 (n ¼ 150) 0 (n ¼ 146)
59.92  29.37 (n ¼ 140) 45.19  17.60 (n ¼ 132)
53.89  29.10 (n ¼ 36 of 42) –
76.65  41.20 (n ¼ 135) 45.19  17.60 (n ¼ 132)
46 (n ¼ 145) 44 (n ¼ 134)
78 (n ¼ 139) 63 (n ¼ 128)
9 (n ¼ 147) 13 (n ¼ 140)
141 (n ¼ 147) 127 (n ¼ 140)
2.84  1.26 (n ¼ 147) 1.45  0.90 (n ¼ 140)
93 (n ¼ 145) 102 (n ¼ 140)
112 (n ¼ 146) 99 (n ¼ 140)
3.89  4.26 (n ¼ 148) 5.10  10.33* (n ¼ 140)
1.47  3.70 (n ¼ 139) 1.66  4.08 (n ¼ 138)
available; N, number of patients in receipt; N-IRA, non-IRA; P-PCI,
her 104 d; if these data are removed, then the IRA mean is 3.96 d and
Table 2 – Unit costs.
Resource use Unit cost (£)
Index admission costs
P-PCI procedure time cost (per
minute)
5.94*
Glycoprotein IIb/IIIa inhibitor:
abciximab
710.15*,† [15]
Bivalirudin 426.25*,‡ [15]
Bare metal stent 97.50*
Drug-eluting stents 301.88*
Femoral access 46.86*
Radial access 26.50*
Thrombus aspiration catheter 160.00*
Disposables§ (cost per sitting) 154.50*
Bed day
Standard care 379.40 [13]
High dependency 851.89 [13]
Intensive care 1236.48 [13]
Re-admission costs (up to 12-mo follow-up)
Bed day (non-MACE) 265.06 [13]
Myocardial infarction 1710.18 þ 224.15 per day if
45 d [13]
Heart failure 2168.19 þ 280.56 per day if
45 d [13]
Revascularization
PCI 2016.59 þ 379.40 per day if
45 d [13]
CABG 9002.01 þ 388.82 per day if
45 d [13]
Health professional visits (most commonly reported)
Cardiologist 125.89 [13]
Hospital nurse 45.00 [14]
General practitioner 25.00 [14]
CABG, coronary artery bypass grafting; MACE, major adverse
cardiac event; P-PCI, primary percutaneous coronary intervention.
* On the basis of a survey of the participating centers.
† 2.8 vials per sitting.
‡ 1.38 vials per sitting.
§ Balloon, sheath, and catheter.
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detailed in Table 2. Total costs were subsequently estimated (see
Table 3), when mean P-PCI procedure(s) costs were lower for IRA-
only patients, although mean index admission length of stay
costs and MACE re-admission costs were both slightly higher for
IRA-only patients (see Table 3). Mean overall hospital costs wereTable 3 – Summary of total costs.
Cost component Complete,
P-PCI procedure(s) time £455.37  £24
P-PCI procedure(s) consumables and equipment £1695.95  £58
Index admission—hospital length of stay £2830.98  £20
Total index admission cost £4890.12  £20
MACE re-admissions £277.92  £12
Other hospital re-admissions £310.83  £93
Overall hospital costs £5551.70  £29
Health professional visits £422.07  £38
Overall NHS and PSS costs £5814.25  £30
n, number of patients for whom data were available; MACE, major ad
percutaneous coronary intervention; PSS, personal social services.estimated to be higher for complete revascularization patients
(£5552 complete [n ¼ 121]; £4919 IRA-only [n ¼ 116]), although
there was no statistically signiﬁcant difference between the two
groups.
In relation to the additional resource use questionnaire,
health professional visit data were provided by 48 (54.5%) of the
88 complete revascularization patients from whom details were
requested, compared with 48 (52.2%) of the 92 IRA-only patients.
In addition, because they would have had no (postdischarge)
health professional visits, these costs were set to 0 for the
patients who died within their index admission (n ¼ 5 IRA-only).
The mean number of health professional visits in the 12-month
follow-up period was 8.7 in the complete revascularization arm,
compared with 10.6 in the IRA-only arm. The associated mean
costs were £422 (n ¼ 48) and £480 (n ¼ 53), respectively. When
health professional visit costs were added to overall hospital
costs to estimate overall NHS and PSS costs, these were esti-
mated to be £5814 (n ¼ 41) for complete revascularization and
£5089 (n ¼ 42) for IRA-only (see Table 3).
The two employment questions in the additional resource use
questionnaire were completed by 48 (54.5%) of the 88 complete
revascularization patients and 48(52.2%) of the 92 IRA-only
patients at the 12-month follow-up point. Of the 25 complete
revascularization patients who reported that they were in
employment at the time of their heart attack, 20 reported they
had returned to work at the 12-month follow-up point. In the
IRA-only arm 15 out of 23, who reported that they were in
employment at the time of their heart attack, reported that they
had returned to work.
Outcomes
Table 4 presents clinical outcomes for both groups on the basis of
available data. Over the 12-month follow-up period, the mean
number of MACEs in the complete revascularization arm was
signiﬁcantly lower (0.14 per patient, 19 events in total) than that
in the IRA-only arm (0.30 per patient, 41 events in total). In terms
of health-related quality of life, the three-level EQ-5D scores were
slightly, nonsigniﬁcantly higher for complete revascularization
patients both at baseline and at 12-month follow-up.
Analyses
Table 5 presents estimates of the mean incremental cost and
incremental effect (MACE or QALY), generated from bivariate
regression, along with ICER and CEAC estimates. For the base
case (intention to treat) and SA1 (per protocol), complete revas-
cularization was estimated to dominate the IRA-only arm, in
terms of both MACEs and QALYs, because it had both lower mean
costs and higher mean effects. Signiﬁcantly fewer MACEsmean  SD IRA-only, mean  SD P value
4.77 (n ¼ 135) £268.46  £104.55 (n ¼ 132) o0.001
3.41 (n ¼ 137) £1183.98  £467.88 (n ¼ 128) o0.001
91.97 (n ¼ 148) £3605.11  £6231.66 (n ¼ 140) 0.164
97.54 (n ¼ 129) £4668.21  £5048.39 (n ¼ 121) 0.654
64.14 (n ¼ 139) £400.88  £1232.14 (n ¼ 138) 0.413
5.73 (n ¼ 139) £251.62  £668.20 (n ¼ 138) 0.545
74.40 (n ¼ 121) £4918.60  £2449.29 (n ¼ 116) 0.074
5.47 (n ¼ 48) £480.43  £368.74 (n ¼ 53) 0.440
41.03 (n ¼ 41) £5089.17  £2101.78 (n ¼ 42) 0.212
verse cardiac event; NHS, National Health Service; P-PCI, primary
Table 4 – Outcomes.
Item Complete (n ¼ 150) IRA-only (n ¼ 146) P value
Baseline EQ-5D-3L score, mean  SD 0.824  0.216 (n ¼ 116) 0.791  0.295 (n ¼ 116) 0.287
12-mo EQ-5D-3L score, mean  SD 0.837  0.256 (n ¼ 122) 0.798  0.311 (n ¼ 115) 0.295
QALY score, mean  SD 0.833  0.204 (n ¼ 103) 0.801  0.258 (n ¼ 100) 0.339
MACE, N 19 (n ¼ 139) 41 (n ¼ 138) 0.016*
Death, N 4 (n ¼ 150) 10 (n ¼ 146) 0.098
Heart failure, N 6 (n ¼ 139) 11 (n ¼ 138) 0.259
Myocardial infarction, N 1 (n ¼ 139) 3 (n ¼ 138) 0.312
Revascularization, N 8 (n ¼ 139) 17 (n ¼ 138) 0.079
EQ-5D-3L, three-level EuroQol ﬁve-dimensional questionnaire; MACE, major adverse cardiac event; n, number of patients for whom data were
available; N, number of events; QALYs, quality-adjusted life-years truncated at 12 mo.
* Statistically signiﬁcant P o 0.05.
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no signiﬁcant difference between groups with regard to either
overall hospital costs or QALYs.
In terms of uncertainty, 49.0% of the cost-effect pairs on the
cost-effectiveness plane were located in the southeast quadrant,
where complete revascularization would be estimated to have
both lower mean costs and higher mean effects. Nevertheless,
there was wide variation in the bootstrap estimates of both the
mean incremental cost and the mean incremental QALY gain (see
Fig. 1). Similarly, according to the CEAC, at £20,000 per QALY, the
probability that complete revascularization was more cost-
effective than IRA-only was approximately 70%, indicating that
there was some uncertainty associated with this decision (see
Appendix Figure in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2017.02.002). In addition, the EVPI (per patient) was
estimated to be £82.73. On the assumption that about one-third of
the 90,000 annual P-PCI procedures for STEMI would be eligible for
complete revascularization [8], over 10 years the population EVPI
would be estimated to be approximately £25 million (at a
willingness-to-pay threshold value of £20,000 per QALY).
As in base-case analyses, all sensitivity analyses estimated
that there was a nonsigniﬁcant difference in mean costs and
QALYs, but a signiﬁcant reduction in MACEs in patients under-
going complete revascularization compared with IRA-only PCI
(see Table 5). For base case and SA1, costs were higher in the IRA-
only group; in SA2 (complete case) however, costs were higher in
the intervention arm. This was largely due to two participants in
the IRA-only group with very high costs (4£50,000). These
participants were excluded from SA2 because some costTable 5 – Estimates of incremental cost, incremental effe
tion in the base-case and sensitivity analyses.
Analysis (Nc, Ni
*) Incremental cost (£) (95% C
Base case: imputed (150, 146) 215.96 (1,390.20 to 958.29
SA1§: imputed per protocol (139, 139) 534.89 (1,730.65 to 660.88
SA2§: complete case (121, 116) 590.63 (91.02 to 1272.27)
Base-case: imputed (150, 146) 215.96 (1,390.20 to 958.29
SA1: imputed per protocol (139, 139) 534.89 (1,730.65 to 660.88
SA2: complete case (89, 86) 446.65 (151.55 to 1,044.86)
CEAC, cost-effectiveness acceptability curve; CI, conﬁdence interval; ICER
event; QALYs, quality-adjusted life-years truncated at 12 mo.
* Nc (Ni) is the number of patients randomized to complete revasculariz
† Probability of being cost-effective on the CEAC at the threshold (λ) of “
‡ “Dominant” refers to lower mean costs and higher mean effect.
§ SA1 and SA2 refer to the ﬁrst and second sensitivity analyses describecomponents were missing; their known costs were, however,
used to estimate the imputation models, and they were included
in base-case and SA1 analyses.Discussion
Main Findings
On the basis of evidence provided from the CvLPRIT [8], because
complete revascularization had both lower mean costs and
higher mean effects compared with IRA-only, we would estimate
complete revascularization to be cost-effective. There is, how-
ever, some uncertainty associated with this decision. For exam-
ple, according to the CEAC it was estimated that there was
approximately a 30% chance (at a willingness-to-pay threshold
value of £20,000 per QALY) of making the wrong decision by
implementing complete revascularization, and the population
EVPI was estimated to be approximately £25 million.
Comparisons with Other Studies
We are not aware of any previous economic evaluations that have
compared complete revascularization with IRA-only for patients
with STEMI with multivessel disease. The ﬁndings of this study
are, however, consistent with previous clinical evidence, which
suggests that complete revascularization reduces future MACEs
[7,9,30,31] (with associated reduced hospital re-admission costs)
and also improves quality of life (according to the Seattle Anginact, and cost-effectiveness of complete revasculariza-
I) Incremental effect (95% CI) ICER CEAC†
MACE
) 0.170 (0.044 to 0.296) Dominant‡
) 0.201 (0.070 to 0.331) Dominant‡
0.156 (0.023 to 0.290) £3,776.87
QALYs (truncared at 12 months
) 0.011 (0.019 to 0.041) Dominant‡ 72.0%
) 0.012 (0.019 to 0.043) Dominant‡ 84.4%
0.021 (0.018 to 0.060) £21,495.69 45.3%
, incremental cost-effectiveness ratio; MACE, major adverse cardiac
ation (IRA-only) who were included in the analysis.
£20,000 per QALY.
d in the Methods section.
Fig. 1 – Bootstrapp estimates (and overall mean) of the
incremental cost and effect of complete revascularization
compared with IRA-only, depicted on the cost-effectiveness
plane. IRA, infarct-related artery; QALYs, quality-adjusted
life-years.
V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ]6Questionnaire) [32]. There are few well-conducted economic
analyses of P-PCI, especially in the context of randomized trials.
When compared with thrombolysis, P-PCI has higher initial costs
that are offset by reduced downstream costs and complications
[33,34]. In the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications trial, P-PCI with stenting
was shown to be cost-effective compared with plain balloon
angioplasty [35]. Although they are based on different treatment
comparisons, and the results may not be generalizable to the
population in our study, these previous studies indicate that
better revascularization in the context of STEMI can be cost-
effective, in spite of higher initial costs.Study Limitations
In line with good practice recommendations for cost-
effectiveness analyses [36], we concentrated on large cost drivers
and excluded resources that were not expected to differ between
the two treatment arms (e.g., routine monitoring scans or tests).
That said, a potential limitation is that a narrow health sector
cost perspective was taken, particularly because patients in only
three centers were asked to complete the additional self-report
questionnaire (reporting health professional visits and employ-
ment status). These costs were excluded from subsequent anal-
yses. The results presented in Table 3 indicate that these were
not the main cost drivers for responding patients. With regard to
health-related quality of life, QALY scores were available for
approximately 70% of participants only (see Table 4). Some of
the missing EQ-5D baseline data may be due to the patient being
discharged at short notice or at the weekend when a research
nurse was not available.
A further potential limitation is that our analysis is based on
the evidence generated by one trial [8] and therefore may not
incorporate all relevant evidence [37]. That said, a recent meta-
analysis [31] shows that our trial results are in keeping with the
few trials that have been conducted in this area. Similarly, it
could be argued that the conclusions might differ if results were
estimated over a longer follow-up period. Nevertheless, if the
treatment effect was maintained beyond 12 months, the con-
clusions would be unchanged because extrapolation would
increase the QALY gain, improving the estimated level of cost-effectiveness. The main strength of this economic analysis is that
it is based on a randomized study [8], an advance on observa-
tional studies that may not control for confounding factors [30].Conclusions
On the basis of an economic evaluation of the CvLPRIT [8], we have
shown that in a population of patients with STEMI with multi-
vessel disease, complete revascularization undertaken during the
index admission was more effective in terms of fewer MACEs, and
had an incremental QALY gain, compared with IRA-only revascu-
larization. Because higher procedure costs are broadly offset by
lower re-admission rates, such that overall costs are similar, these
data suggest that complete revascularization constitutes a cost-
effective treatment option for patients with STEMI with multi-
vessel disease. That said, the CEAC and EVPI values suggest that
there is some uncertainty associated with this decision.
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